Abstract:Purpose: Understanding resistance to selective FGFR inhibitors is crucial to improve the clinical outcomes of patients with FGFR2-driven malignancies. Experimental Design: We analyzed sequential ctDNA, +/- WES or targeted NGS on tissue biopsies from patients with tumors harboring activating FGFR2 alterations progressing on pan-FGFR-selective inhibitors, collected in the prospective UNLOCK program. FGFR2::BICC1 Ba/F3 and patient-derived xenografts (PDX) models were used for functional studies. Results: Thirty-six patients were included. In cholangiocarcinoma, at resistance to both reversible inhibitors (e.g. pemigatinib, erdafitinib) and the irreversible inhibitor futibatinib, polyclonal FGFR2 kinase domain mutations were frequent (14/27 patients). Tumors other than cholangiocarcinoma shared the same mutated FGFR2 residues, but polyclonality was rare (1/9 patients). At resistance to reversible inhibitors, 14 residues in the FGFR2 kinase domain were mutated; after futibatinib, only the molecular brake N550 and the gatekeeper V565. Off-target alterations in PI3K/mTOR and MAPK pathways were found in 11 patients, often together with on-target mutations. At progression to a first FGFR inhibitor, 12 patients received futibatinib or lirafugratinib (irreversible inhibitors), with variable clinical outcomes depending on previous resistance mechanisms. Two patients with TSC1 or PIK3CA mutations benefitted from everolimus. In cell viability assays on Ba/F3 and in pharmacologic studies on PDX, irreversible inhibitors retained better activity against FGFR2 kinase domain mutations, with lirafugratinib active against the recalcitrant V565L/F/Y. Conclusions: At progression to FGFR inhibitors, FGFR2-driven malignancies are characterized by high intra- and inter-patient molecular heterogeneity, particularly in cholangiocarcinoma. Resistance to FGFR inhibitors can be overcome by sequential, molecularly-oriented treatment strategies across FGFR2-driven tumors.

FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions

A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality

Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance

Molecular Targeting of the Fibroblast Growth Factor Receptor Pathway across Various Cancers

Targeting FGFR for cancer therapy

Targeting FGFRs for Tumor Therapy: Current Status and Novel Strategies

Recent developments and advances of FGFR as a potential target in cancer

FGFR Families: Biological Functions and Therapeutic Interventions in Tumors

Therapeutic implications of fibroblast growth factor receptor inhibitors in a combination regimen for solid tumors

Fibroblast Growth Factor Receptors (fgfrs): Structures and Small Molecule Inhibitors

Targeting FGFR Pathways in Gastrointestinal Cancers: New Frontiers of Treatment

Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer

Biological Significance and Targeting of the FGFR Axis in Cancer

Recent Advances in Tumor Therapy Targeting FGFR

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors

A FGFR1 inhibitor patent review: progress since 2010

Understanding and Overcoming Resistance to Selective FGFR inhibitors Across FGFR2 -Driven Malignancies

FGFR-TKI Resistance in Cancer: Current Status and Perspectives

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

Targeting Fibroblast Growth Factor Receptor Pathway: Precision Medicine for Biliary Cancer and Beyond

Small Molecule Inhibition of Fibroblast Growth Factor Receptors in Cancer